An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primatesResearch in context

Summary: Background: Angiopoietin-like protein 4 (ANGPTL4) inhibition is a promising approach to manage atherogenic dyslipidaemia and residual atherosclerotic cardiovascular disease (ASCVD) risk. Human ANGPTL4 loss-of-function (LoF) is associated with reduced plasma triglyceride (TG), remnant chole...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Beryl B. Cummings, Page R. Bouchard, Mark N. Milton, Peter F. Moesta, Vyas Ramanan, John W. Trauger, Eleftheria Maratos-Flier, Andrei Voznesensky, Igor Splawski, Amitabh V. Nimonkar, Keith DiPetrillo, Daniel LaSala, Meihui Pan, Meghan M. Flaherty, Francois Huet, Sukhdeep K. Sahambi, Jijun Dong, Deborah Knee, Regis Cebe, Thomas Huber, Joshua Lehrer-Graiwer, Rebecca A. Juliano, Ethan J. Weiss
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2025-07-01
סדרה:	EBioMedicine
נושאים:	MAR001 ANGPTL4 Triglyceride Remnant cholesterol Non-human primates Safety
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S2352396425001926
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!